Journal Article

FROM SEEING TO BELIEVING: A 43-YEAR LONG JOURNEY IN IMMUNOSTAINING

2025

Overview

In the last 43 years, thanks to fantastic collaborators, we used antibodies in immunostaining and published a few firsts: TP53 in breast cancer (1988), FFPE-proofs anti Ki-67 antibody MIB 1 and the citrate antigen retrieval buffer (1992), reticular cells in human bone marrow (1993), BCL6 in germinal centers (1995), PRDM1 in plasma cells (2005), the sub cellular localization and distribution of AID and the function of IRF4 (2006). From 2013 to 2021 we dissected the effects of tissue processing on antigenicity, a body of discoveries which led to a hyperplexed (>15 markers) multiplexing method, Multiple Iterative Labeling by Antibody Neodeposition (MILAN)1,2. The application of MILAN and the complexity of data obtained ( 100 markers, millions of single cells) landed us in the rarefied world of dimensionality reduction algorithms, where math rules and statistical significance replaces “representative images”. Because of these latest developments, we discovered that the human eye ability to discriminate shades of grey is very limited (less than 64/256)3, thus low levels of staining are routinely missed and eye-guided assessment is unreliable. Bioinformatics tools we developed (BRAQUE)4 provides highest sensitivity, granularity and robustness based on objective statistical parameters. Biologists and Pathologists need to believe (in math)5 rather than see with their own flawed eyes.

• Publisher: PAGEPress Publications
• Subject: DEVELOPMENT, VALIDATION AND APPLICATION OF MULTIPLEX IMMUNOHISTOCHEMICAL ASSAYS